Gender in Politics

Women’s political participation and representation vary dramatically within and between countries. We selectively review the literature on gender in politics, focusing on women’s formal political participation. We discuss both traditional explanations for women’s political participation and representation, such as the supply of women and the demand for women, and newer explanations such as the role of international actors and gender quotas. We also ask whether women are distinctive—does having more women in office make a difference to public policy? Throughout the review we demonstrate that a full understanding of women’s political representation requires both deep knowledge of individual cases such as the United States and broad knowledge comparing women’s participation across countries. We end with four recommended directions for future research: (a) globalizing theory and research, (b) expanding data collection, (c) remembering alternative forms of women’s agency, and (d ) addressing intersectionality

Call to (In)Action: The Effects of Racial Priming on Grassroots Mobilization

Previous work on the effects of race on the political behaviors of white Americans is beset with two problems. First, much of the work on the effect of race has looked primarily at attitudes as opposed to political action around a policy. Second, studies of the relationship between race and policy have revolved around issues for which it is inherently difficult to separate the effects of racial prejudice from conservative ideology. To address these problems, we examine the willingness of individuals to write their member of Congress in support of a non-racial political cause, which we experimentally treat with racial cues. We also experimentally present a comparison with a non-racial but similar ‘specialized’ group, which allows us to distinguish concerns about race from concerns about specialized benefits objectionable to conservatives. We show that whites with higher levels of racial resentment are less likely to act politically in support of a policy perceived as benefiting ethnic and racial minorities

Liraglutide and Renal Outcomes in Type 2 Diabetes.

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach. Changes in the estimated glomerular filtration rate and albuminuria were also analyzed. RESULTS: A total of 9340 patients underwent randomization, and the median follow-up of the patients was 3.84 years. The renal outcome occurred in fewer participants in the liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of 4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). This result was driven primarily by the new onset of persistent macroalbuminuria, which occurred in fewer participants in the liraglutide group than in the placebo group (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). The rates of renal adverse events were similar in the liraglutide group and the placebo group (15.1 events and 16.5 events per 1000 patient-years), including the rate of acute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively). CONCLUSIONS: This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .)